ATE357214T1 - Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation - Google Patents

Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation

Info

Publication number
ATE357214T1
ATE357214T1 AT97955033T AT97955033T ATE357214T1 AT E357214 T1 ATE357214 T1 AT E357214T1 AT 97955033 T AT97955033 T AT 97955033T AT 97955033 T AT97955033 T AT 97955033T AT E357214 T1 ATE357214 T1 AT E357214T1
Authority
AT
Austria
Prior art keywords
inhalation
neoplasms
preparation
treatment
production
Prior art date
Application number
AT97955033T
Other languages
English (en)
Inventor
Michael E Placke
Anthony R Imondi
Michael J Booker
John E Frye
Praful K Shah
Douglas R Flanagan Jr
Maureen D Donovan
Original Assignee
Battelle Memorial Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute filed Critical Battelle Memorial Institute
Application granted granted Critical
Publication of ATE357214T1 publication Critical patent/ATE357214T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97955033T 1996-12-30 1997-12-30 Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation ATE357214T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3378996P 1996-12-30 1996-12-30

Publications (1)

Publication Number Publication Date
ATE357214T1 true ATE357214T1 (de) 2007-04-15

Family

ID=21872447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97955033T ATE357214T1 (de) 1996-12-30 1997-12-30 Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation

Country Status (12)

Country Link
US (5) US6471943B1 (de)
EP (1) EP0954283B1 (de)
JP (1) JP2001513078A (de)
CN (1) CN1245423A (de)
AT (1) ATE357214T1 (de)
AU (1) AU741439B2 (de)
BR (1) BR9713661A (de)
CA (2) CA2275889C (de)
DE (1) DE69737510T2 (de)
ES (1) ES2285743T3 (de)
NZ (1) NZ336381A (de)
WO (1) WO1998029110A2 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
WO2000019991A1 (en) * 1998-10-02 2000-04-13 Battelle Memorial Institute Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
WO2000045805A2 (en) * 1999-02-08 2000-08-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US7883032B2 (en) * 2000-04-03 2011-02-08 Battelle Memorial Institute Devices and formulations
US7585666B2 (en) 2001-10-19 2009-09-08 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
MXPA03004883A (es) * 2000-12-01 2004-05-04 Battelle Memorial Institute Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
WO2003015521A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
ES2625340T3 (es) * 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
ATE433961T1 (de) * 2002-02-08 2009-07-15 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
EP1487413A4 (de) * 2002-03-05 2010-11-10 Transave Inc Inhalationssystem zur prävention und behandlung von intrazellulären infektionen
ITPI20020018A1 (it) * 2002-03-28 2002-06-26 Azienda Ospedaliera Pisana Ventilazione polmonare a variazione di flusso
GB0208516D0 (en) * 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US7677411B2 (en) * 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
WO2004002395A2 (en) * 2002-06-27 2004-01-08 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluating non-pharmaceutical dry powders
KR20050038011A (ko) * 2002-08-02 2005-04-25 트랜세이브, 인코포레이티드 백금 응집체 및 이의 제조 방법
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
KR101424980B1 (ko) * 2002-10-29 2014-08-01 인스메드 인코포레이티드 항감염제의 지속적인 방출
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US20060179491A1 (en) * 2002-11-12 2006-08-10 Brian Graham Process for treating non-human animals
US7353533B2 (en) 2002-12-18 2008-04-01 Novell, Inc. Administration of protection of data accessible by a mobile device
US7185650B2 (en) * 2002-12-19 2007-03-06 Arie Huber Systems and methods for determining a minimum effective dose of an inhaled drug for an individual patient at a given time
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20040187864A1 (en) * 2003-03-24 2004-09-30 Cindet, Llc Inhalation device and method
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US7377277B2 (en) * 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
US7451761B2 (en) * 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
EP1729786A4 (de) * 2004-03-18 2008-03-26 Transave Inc Verabreichung von cisplatin durch inhalation
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
JP5735724B2 (ja) * 2004-11-08 2015-06-17 インスメッド， インコーポレイテッド 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
CN101189006A (zh) * 2005-04-07 2008-05-28 康福玛医药公司 基于磷脂的药物制剂及其生产和使用方法
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US20090180964A1 (en) * 2005-06-24 2009-07-16 Rao Papineni Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
JP2009518302A (ja) * 2005-12-01 2009-05-07 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン含有組成物
CA2896083A1 (en) 2005-12-08 2007-06-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
CA2652926A1 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
HUE031982T2 (en) 2007-02-26 2017-08-28 Heartbeet Ltd Performance enhancer and its use
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
US20100196455A1 (en) * 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
EP2534957B1 (de) 2007-12-14 2015-05-27 AeroDesigns, Inc Abgabe von Aerosol-sprühbaren Produkten
AU2009302387B2 (en) * 2008-10-07 2014-12-04 Rexahn Pharmaceuticals, Inc HPMA - docetaxel or gemcitabine conjugates and uses therefore
CN102686243B (zh) 2009-10-13 2015-02-18 瑞沙恩医药公司 用于抗癌剂递送的聚合物系统
US9566234B2 (en) 2012-05-21 2017-02-14 Insmed Incorporated Systems for treating pulmonary infections
CN115414384A (zh) 2012-09-04 2022-12-02 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
US9801874B2 (en) 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
EP3581186A1 (de) 2012-11-29 2019-12-18 Insmed Incorporated Stabilisierte vancomycin-formulierungen
AU2013359048A1 (en) * 2012-12-13 2015-07-02 Cytrx Corporation Anthracycline formulations
EP3003489B1 (de) 2013-06-05 2021-08-18 CytRx Corporation Zytotoxische mittel zur behandlung von krebs
EP3027212A1 (de) * 2013-08-02 2016-06-08 Children's Hospital Medical Center Zusammensetzungen und verfahren zur behandlung von krankheitszuständen im zusammenhang mit aktivierten t-zellen und/oder b-zellen
EP3054948B1 (de) 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin zur behandlung von lymphangioleiomyomatose
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CA2939342A1 (en) 2014-02-11 2015-08-20 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015154084A1 (en) 2014-04-04 2015-10-08 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
TWI601542B (zh) * 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
DK3142643T3 (da) 2014-05-15 2019-10-14 Insmed Inc Fremgangsmåder til behandling af ikke-tuberkuløse mykobakterielle lungeinfektioner
MX2017004440A (es) 2014-10-07 2017-11-01 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
PT3302431T (pt) 2015-06-04 2020-11-30 Crititech Inc Partículas de taxano e a sua utilização
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
EP3335126A4 (de) 2015-08-11 2019-05-01 Cognoa, Inc. Verfahren und vorrichtung zur bestimmung des entwicklungsfortschritts mit künstlicher intelligenz und benutzereingabe
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
JP6970683B2 (ja) 2016-04-04 2021-11-24 クリティテック・インコーポレイテッド 固形腫瘍治療のための方法
US10874768B2 (en) * 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
EP3580700A4 (de) * 2017-02-09 2020-11-18 Cognoa, Inc. Plattform und system für digitale personalisierte medizin
JP2020523285A (ja) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療
KR102303762B1 (ko) * 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
CA3134521A1 (en) 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
CN111067879B (zh) * 2020-01-20 2022-08-09 珠海瑞思普利医药科技有限公司 一种抗肿瘤组合物吸入粉雾剂及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246399A (en) 1977-03-21 1981-01-20 Interx Research Corporation Complexes of doxorubicin exhibiting enhanced stability
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4560774A (en) 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
JPS63500175A (ja) * 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド リポソ−ム吸入法および吸入システム
US5124318A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
GB8519452D0 (en) 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
US4975421A (en) 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4826817A (en) 1986-02-07 1989-05-02 Brown Thomas E Amino acid and hydroxyamino acid transporter compounds for therapeutic applications, process and use
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5115971A (en) 1988-09-23 1992-05-26 Battelle Memorial Institute Nebulizer device
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5171737A (en) 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
ES2087911T3 (es) 1989-04-28 1996-08-01 Riker Laboratories Inc Dispositivo de inhalacion de polvo seco.
HUT61487A (en) 1989-12-20 1993-01-28 Brigham & Womens Hospital Process for producing aerosol pharmaceutical composition comprising autoantigens
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5348946A (en) 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
US5681812A (en) 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5283383A (en) 1992-02-13 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Antitumor compound, compositions and method of use
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
US5622960A (en) 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
AU1875292A (en) 1992-05-04 1993-11-29 Adria Laboratories Inc. Methods for treating cancer using high-dose epirubicin
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
EP1500393A1 (de) 1992-11-27 2005-01-26 Mayne Pharma (USA) Inc. Injizierbare Arzneizubereitung welche Taxol enthält
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
EP0673240B1 (de) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilisierte medizinische aerosollösungen
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5594139A (en) 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JPH08301762A (ja) * 1995-05-12 1996-11-19 Teijin Ltd 肺癌治療剤
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Also Published As

Publication number Publication date
US6419900B2 (en) 2002-07-16
EP0954283A2 (de) 1999-11-10
US20010036444A1 (en) 2001-11-01
AU741439B2 (en) 2001-11-29
ES2285743T3 (es) 2007-11-16
WO1998029110A2 (en) 1998-07-09
BR9713661A (pt) 2000-10-24
US20020155066A1 (en) 2002-10-24
JP2001513078A (ja) 2001-08-28
US6348209B2 (en) 2002-02-19
AU7097598A (en) 1998-07-31
CA2275889A1 (en) 1998-07-09
US20010038826A1 (en) 2001-11-08
US20010038827A1 (en) 2001-11-08
CA2628857C (en) 2011-09-13
DE69737510T2 (de) 2007-12-06
CA2275889C (en) 2008-03-18
CN1245423A (zh) 2000-02-23
NZ336381A (en) 2000-11-24
CA2628857A1 (en) 1998-07-09
WO1998029110A3 (en) 1999-04-15
US6471943B1 (en) 2002-10-29
US6419901B2 (en) 2002-07-16
EP0954283B1 (de) 2007-03-21
DE69737510D1 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
ATE357214T1 (de) Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
WO2001066103A3 (en) Treatment of neoplasms by inhalation of carboplatin
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
AU645023B2 (en) Compositions and method for treating painful, inflammatory or allergic disorders
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
DE69328635D1 (de) Verwendung eines stoffgemisches enthaltend alpha hydroxy organische säure zur herstellung eines arzneimittels zur behandlung von kleinen mundgeschwüren
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATA21888A (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
KR950016760A (ko) 치질 치료제
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties